Summary of Ionis Pharmaceuticals Conference Call Company Overview - **Company**: Ionis Pharmaceuticals (NasdaqGS:IONS) - **Event**: 2026 Global Healthcare Conference - **Date**: March 09, 2026 Key Points Ongoing Product Launches - **TRYNGOLZA Launch**: The company is transitioning from the TRYNGOLZA launch to the upcoming SHTG launch, involving label changes and pricing adjustments [2][6] - **2025 Performance**: 2025 was a pivotal year with TRYNGOLZA achieving $108 million in product revenue, exceeding estimates [7] - **SHTG Patient Population**: Severe hypertriglyceridemia (SHTG) is estimated to affect over 3 million people in the U.S., with 1 million at high risk for acute pancreatitis [8] Competitive Landscape - **Pricing Pressure**: A new competitor has entered the FCS market with a significantly lower price, leading to some pricing pressure for TRYNGOLZA [9] - **First-Mover Advantage**: The company believes it has a year to a year and a half head start over competitors for the SHTG market, which is crucial for capturing the high-risk patient population [17] Clinical Data and Efficacy - **Phase 3 Data**: The company reported an 85% reduction in acute pancreatitis and a 72% reduction in triglycerides on top of standard care, which is expected to drive physician enthusiasm [10][21] - **Liver Fat Observations**: A small but statistically significant increase in liver fat was observed in clinical studies, but it is not considered an adverse event and is expected to return to baseline over time [25][27] Market Opportunities - **U.S. Market Potential**: The peak product sales for TRYNGOLZA and SHTG in the U.S. have been increased to over $2 billion based on healthcare provider demand [11] - **International Expansion**: The company has partnered with Sobi for commercialization in Europe, focusing on the most severe patient populations [30] Future Developments - **CARDIO-TTRansform Study**: The company is looking forward to phase 3 data for cardiomyopathy, which could significantly expand its market presence [33] - **Lp(a) HORIZON Study**: Targeting Lp(a) with pelacarsen, the study is expected to achieve a 20%-25% relative risk reduction, representing a multi-billion dollar opportunity [43] Strategic Positioning - **Innovation Focus**: Ionis is committed to innovation in oligonucleotide therapeutics, with follow-on molecules in development for less frequent dosing and targeting CNS diseases [51][52] - **Competitive Strategy**: The company aims to maintain its leadership by focusing on product efficacy, safety, and innovative delivery methods [51] Additional Insights - **Market Dynamics**: The competitive landscape for oligonucleotide therapeutics is becoming more crowded, but Ionis plans to differentiate through innovation and first-mover advantages [50] - **Patient-Centric Approach**: The company emphasizes the importance of addressing unmet medical needs and ensuring patient access to treatments [11][30]

Core Viewpoint - PepGen Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and efficacy of its lead product candidate, PGN-EDO51, and the adequacy of its clinical trials [3][4][5]. Company Overview - PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases, with PGN-EDO51 targeting Duchenne muscular dystrophy (DMD) [3]. Allegations and Events - The class action lawsuit claims that PepGen made false statements about PGN-EDO51's safety and effectiveness, inadequately conducted the CONNECT2 clinical trial, and overstated the product's clinical and regulatory prospects [3]. - On July 30, 2024, PepGen reported "positive clinical data" from the CONNECT1 study, but the results were deemed disappointing by analysts, leading to a nearly 33% decline in stock price [4]. - On December 16, 2024, PepGen received a clinical hold notice from the FDA regarding the CONNECT2 study, causing further stock decline [5]. - On January 29, 2025, dosing in the CONNECT1 study was paused due to safety concerns, resulting in an approximate 22% drop in stock price [6]. - On March 4, 2025, PepGen announced a voluntary temporary pause of the CONNECT2 study, leading to another nearly 19% decline in stock price [7].